What You Should Know:
– Arine, a San Francisco-based next-generation medication intelligence company raises $29M in a Series B round funding composed of equity and debt financing led by 111° West Capital, with participation from new investors MBX Capital and New Leaf Ventures, and continued support from Katalyst Ventures.
– Founded in 2017, Arine helps health plans substantially decrease the cost of care and improve patient outcomes by reducing medication errors, avoiding complications, and keeping patients out of the hospital.
– Arine plans to use the latest funding to advance the capabilities of its platform to enable value-based care at scale, not only for health plans and risk-bearing providers, but also to expand its offerings to other channel partners across the value-based care continuum that can leverage Arine’s medication intelligence to achieve next-level outcomes.
